Bioactive stents for type II diabetics and methods for use thereof
First Claim
1. A bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer, wherein the polymer comprises at least one. bioligand covalently bound to the polymer wherein the bioligand binds specifically to integrin receptors on progenitors of endothelial cells (PECs) in circulating blood.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is based on the discovery that a vascular stent or other implantable medical device can be coated with a biodegradable biocompatible polymer to which is attached a bioligand that specifically captures progenitors of endothelial cells (PECs) from the circulating blood to promote endogenous formation of healthy endothelium in Type II diabetics. In one embodiment, the bioligand is a peptide that specifically binds to an integrin receptor on PECs. The invention also provides methods for using such vascular stents and other implantable devices to promote vascular healing in Type II diabetics, for example following mechanical intervention.
-
Citations
66 Claims
- 1. A bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer, wherein the polymer comprises at least one. bioligand covalently bound to the polymer wherein the bioligand binds specifically to integrin receptors on progenitors of endothelial cells (PECs) in circulating blood.
- 33. A kit comprising a bioactive implantable stent comprising a stent structure with a surface coating of a biodegradable, bioactive polymer and at least one bioligand or first member of a specific binding pair is covalently bound to the biodegradable, biocompatible polymer, wherein the bioligand or the first member binds specifically to a target on therapeutic PECs.
- 39. A tubular sheath comprising a biodegradable, bioactive polymer, wherein the polymer comprises at least one bioligand covalently bound to the polymer, wherein the bioligand specifically binds to an integrin receptors on PECs.
-
48. A method comprising using a polymer as a medical device, a pharmaceutical, or as a carrier for covalent immobilization of a bioligand or first member of a specific binding pair that specifically attaches to an integrin receptor in PECs in the circulating blood of a patient with Type II diabetes into which the polymer is implanted, wherein:
-
a) the bioligand forms a specific binding pair with the integrin receptor on PECs in circulating blood;
b) the bioligand forms a specific binding pair with an antibody that binds specifically to the integrin receptor;
orc) the antibody is tagged with a first member of a specific binding pair and the bioligand comprises a second member of the specific binding pair. - View Dependent Claims (49, 50, 51, 52, 53, 54)
-
- 55. An implantable medical device having a biodegradable, bioactive polymer coated upon at least a portion of a surface thereof, wherein the polymer comprises at least one bioligand covalently bound to the polymer, wherein the bioligand specifically binds an integrin receptor on PECs found in peripheral blood.
Specification